Profile data is unavailable for this security.
About the company
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
- Revenue in NOK (TTM)0.00
- Net income in NOK-5.56m
- Incorporated2009
- Employees1.00
- LocationThor Medical ASAKjelsasveien 168 BOSLO 0884NorwayNOR
- Phone+47 22183301
- Fax+47 22580007
- Websitehttps://www.nordicnanovector.com/
More ▼
Mergers & acquisitions
| Acquired company | TRMED:OSL since announced | Transaction value |
|---|---|---|
| Thor Medical AS | 42.93% | 7.96m |
Data delayed at least 15 minutes, as of May 08 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saniona AB | 16.85m | -95.89m | 199.07m | 23.00 | -- | -- | -- | 11.81 | -1.28 | -1.28 | 0.226 | -0.2895 | 0.1546 | -- | 4.71 | 732,173.90 | -87.96 | -59.16 | -108.11 | -70.15 | -213.08 | -970.05 | -568.94 | -1,483.55 | -- | -3.18 | 1.44 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
| InDex Pharmaceuticals Holding AB | 108.43m | -56.53m | 215.39m | 7.00 | -- | 0.912 | -- | 1.99 | -0.1037 | -0.1037 | 0.2028 | 0.443 | 0.3559 | -- | -- | 15,477,000.00 | -18.55 | -37.64 | -21.24 | -41.14 | -46.98 | -450.51 | -52.13 | -454.62 | -- | -- | 0.0086 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
| Corline Biomedical AB | 25.05m | -1.81m | 216.17m | 13.00 | -- | 2.31 | -- | 8.63 | -0.0841 | -0.0841 | 1.16 | 4.34 | 0.248 | -- | 10.92 | 1,925,385.00 | -1.79 | -5.71 | -1.92 | -6.24 | 113.38 | 128.60 | -7.22 | -38.46 | -- | -89.40 | 0.00 | -- | 6.28 | 74.14 | -177.67 | -- | 62.51 | -- |
| Exact Therapeutics AS | 0.00 | -48.33m | 227.77m | 8.00 | -- | 5.05 | -- | -- | -1.51 | -1.51 | 0.00 | 1.41 | 0.00 | -- | -- | -- | -67.21 | -40.21 | -86.14 | -45.67 | -- | -- | -- | -- | -- | -16,578.57 | 0.0258 | -- | -- | -- | -20.52 | -- | -- | -- |
| SenzaGen AB | 49.91m | -22.12m | 229.99m | 34.00 | -- | 3.40 | -- | 4.61 | -0.9136 | -0.9136 | 2.06 | 2.80 | 0.4594 | 3.04 | 4.03 | 1,466,765.00 | -20.35 | -25.84 | -27.59 | -29.85 | 70.05 | 68.62 | -44.31 | -132.29 | 1.22 | -- | 0.0242 | -- | 19.39 | 90.32 | 11.30 | -- | -21.10 | -- |
| Ultimovacs ASA | 0.00 | -189.24m | 241.87m | 27.00 | -- | 0.8657 | -- | -- | -5.50 | -5.50 | 0.00 | 8.12 | 0.00 | -- | -- | 0.00 | -44.08 | -28.80 | -50.02 | -31.12 | -- | -- | -- | -- | -- | -- | 0.0131 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Lipum AB (publ) | 0.00 | -37.21m | 244.26m | -- | -- | 13.86 | -- | -- | -4.05 | -4.05 | 0.00 | 0.4726 | 0.00 | -- | -- | -- | -159.35 | -127.85 | -206.31 | -184.50 | -- | -- | -- | -293,228.70 | -- | -- | 0.2781 | -- | -- | -- | 2.38 | -- | -- | -- |
| Lumito AB (publ) | 0.00 | -25.83m | 250.00m | 15.00 | -- | 2.42 | -- | -- | -0.125 | -0.125 | 0.00 | 0.4997 | 0.00 | -- | -- | 0.00 | -19.98 | -20.77 | -22.14 | -22.38 | -- | -- | -- | -- | 1.42 | -- | 0.0884 | -- | -- | -- | 4.56 | -- | -- | -- |
| Thor Medical ASA | 0.00 | -5.56m | 250.35m | 1.00 | -- | 0.9207 | -- | -- | -0.0318 | -0.152 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -2.52 | -79.17 | -2.84 | -113.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Abliva AB | 137.12k | -95.59m | 258.07m | 6.00 | -- | 2.86 | -- | 1,882.13 | -0.0904 | -0.0904 | 0.0001 | 0.067 | 0.001 | -- | 0.0034 | -- | -70.40 | -74.59 | -80.95 | -86.98 | -14,491.24 | -- | -69,714.60 | -65,958.89 | -- | -- | 0.00 | -- | 341.94 | 93.89 | -12.02 | -- | -19.74 | -- |
| Arctic Bioscience AS | 33.75m | -45.51m | 263.84m | 20.00 | -- | 1.02 | -- | 7.82 | -1.79 | -1.79 | 1.33 | 10.19 | 0.1075 | 0.7025 | 2.93 | 1,687,501.00 | -14.50 | -- | -16.61 | -- | 28.96 | -- | -134.86 | -- | 2.53 | -- | 0.0079 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Aqua Bio Technology ASA | 13.51m | -1.50m | 270.64m | 2.00 | -- | 12.58 | 312.66 | 20.03 | -0.1599 | -0.1599 | 0.4938 | 0.3673 | 0.3079 | 0.6548 | 9.01 | -- | -3.42 | -80.72 | -6.75 | -125.29 | 66.69 | 5.57 | -11.12 | -965.98 | 0.1044 | 0.611 | 0.7538 | -- | 349.88 | 42.04 | 1.97 | -- | -- | -- |
| Lytix Biopharma AS | 3.99m | -87.94m | 276.16m | -- | -- | 4.32 | -- | 69.19 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.037 | -- | 0.4091 | -- | -81.63 | -57.34 | -94.30 | -66.09 | -- | -- | -2,203.36 | -4,665.04 | -- | -- | -- | -- | 183.25 | 63.94 | -57.01 | -- | -- | -- |
| Xbrane Biopharma AB | 238.93m | -322.31m | 291.46m | 93.00 | -- | 0.2922 | -- | 1.22 | -1.27 | -1.52 | 0.943 | 0.6516 | 0.3553 | 2.59 | 357.65 | 2,566,979.00 | -47.92 | -40.98 | -82.48 | -67.24 | 14.82 | -- | -134.89 | -364.40 | 1.09 | -- | 0.2466 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| SynAct Pharma AB | 0.00 | -216.00m | 299.86m | 5.00 | -- | 1.46 | -- | -- | -6.54 | -6.54 | 0.00 | 4.95 | 0.00 | -- | -- | 0.00 | -116.46 | -125.17 | -130.53 | -151.70 | -- | -- | -- | -- | -- | -- | 0.0036 | -- | -- | -- | -117.54 | -- | -- | -- |
Data as of May 08 2024. Currency figures normalised to Thor Medical ASA's reporting currency: Norwegian Krone NOK
0.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Storebrand Asset Management ASas of 31 Jan 2024 | 605.65k | 0.26% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 1.12k | 0.00% |
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
